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Endometriosis is a debilitating disease characterized
by the growth of ectopic endometrial tissue. It is
widely accepted that angiogenesis plays an integral
part in the establishment and growth of endometri-
otic lesions. Recent data from a variety of angiogene-
sis-dependent diseases suggest a critical role of bone
marrow–derived endothelial progenitor cells (EPCs) in
neovascularization. In this study we examined the
blood levels of EPCs and mature circulating endothelial
cells in a mouse model of surgically induced endome-
triosis. Fluorescence-activated cell sorting analysis re-
vealed elevated levels of EPCs in the blood of mice with
endometriosis compared with control subject that un-
derwent a sham operation. EPC concentrations posi-
tively correlated with the amount of endometriotic tis-
sue and peaked 1 to 4 days after induction of disease. In
a green fluorescent protein bone marrow transplant
experiment we found green fluorescent protein–posi-
tive endothelial cells incorporated into endometriotic
lesions but not eutopic endometrium, as revealed by
flow cytometry and immunohistochemistry. Finally,
treatment of endometriosis-bearing mice with the an-
giogenesis inhibitor Lodamin, an oral nontoxic formu-
lation of TNP-470, significantly decreased EPC levels
while suppressing lesion growth. Taken together, our
data indicate an important role for bone marrow–
derived endothelial cells in the pathogenesis of endo-
metriosis and support the potential clinical use of
anti-angiogenic therapy as a novel treatment modality
for this disease. (Am J Pathol 2011, 178:1782–1791; DOI:
10.1016/j.ajpath.2010.12.037)
Endometriosis, or extra-uterine endometrial-like tissue,
affects approximately 10% of women during their repro-
ductive years.
1 The disease causes debilitating pain and
severely affects quality of life with symptoms mimicking
those associated with other chronic pain disorders, such
as irritable bowel syndrome and pelvic inflammatory dis-
ease. In addition, endometriosis is closely associated
with infertility.
2 The diagnosis is usually made upon visual
inspection of the pelvis during laparoscopy; noninvasive
diagnostic tools, such as ultrasound scanning, can reli-
ably detect only severe forms of the disease, such as
ovarian endometriotic cysts.
3 As a result, women can
suffer for 8 to 12 years before receiving a definitive diag-
nosis and appropriate treatment.
4 A biomarker of endo-
metriosis would be invaluable to aid in earlier diagnosis
and to monitor therapeutic efficacy.
The treatment options and success rates are limited,
partially because of a lack of understanding of the patho-
genesis of endometriosis. Treatments include use of hor-
monal drugs to suppress ovarian function, surgical abla-
tion of endometriotic lesions, and, if necessary, removal
Supported by the Endometriosis Millennium Fund from the Royal College
of Obstetrics and Gynaecology, United Kingdom; an MRC New Investi-
gator Award (G0601458 to C.M.B.); the Oxford Partnership Comprehen-
sive Biomedical Research Centre with funding from the Department of
Health’s NIHR Biomedical Research Centres scheme (C.M.B.); and a
grant from the Sydney Swensrud Foundation (R.J.D.). C.M.B. was sup-
ported by a Postdoctoral Research Exchange Fellowship from the Max
Kade Foundation. P.B. was supported by an Alberta Heritage Foundation
for Medical Research Clinical Fellowship. S.R. was supported by the
Garrett B. Smith Foundation.
Accepted for publication December 23, 2010.
Supplemental material for this article can be found on http://ajp.
amjpathol.org or at doi: 10.1016/j.ajpath.2010.12.037.
Address reprint requests to Christian M. Becker, M.D., Nuffield Depart-
ment of Obstetrics/Gynaecology, University of Oxford, John Radcliffe
Hospital, Oxford OX3 9DU, United Kingdom. E-mail: christian.becker@
obs-gyn.ox.ac.uk.
The American Journal of Pathology, Vol. 178, No. 4, April 2011
Copyright © 2011 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ajpath.2010.12.037
1782of the pelvic organs. In the United States, endometriosis
is the third-leading gynecological cause for hospitaliza-
tion and is associated with significant costs.
5,6 In addi-
tion, patients with endometriosis have an increased risk
of ovarian cancer and non-Hodgkin’s lymphoma,
7,8
which adds to the burden of the disease.
Although the pathogenesis of endometriosis remains
uncertain, recent studies by our group and others have
demonstrated that the development of a vascular supply
is essential for the establishment and growth of endo-
metriotic lesions.
9,10 Thus inhibition of angiogenesis has
been suggested as a novel therapeutic approach
11 and
has shown promise in preclinical studies.
12–15 Neovas-
cularization occurs as a result of local sprouting of endo-
thelial cells, elongation of pre-existing blood vessels, or
de novo vasculogenesis.
16 Elevated local or systemic
levels of angiogenic factors not only result in migration
and proliferation of endothelial cells but also recruit en-
dothelial cells from the bone marrow.
17,18 Vascular endo-
thelial growth factor (VEGF), which is highly up-regulated
in endometriotic lesions, eutopic endometrium, and peri-
toneal fluid of patients with endometriosis,
19–21 is a
strong stimulus for the recruitment of bone marrow–de-
rived endothelial progenitor cells (EPCs).
22 Elevated
VEGF serum levels in patients with endometriosis have
been reported by some researchers
23 but not by oth-
ers,
24 which may be due to the short half-life of VEGF of
approximately 3 minutes.
25 Considerable debate cur-
rently exists about the contribution of EPCs to neovascu-
larization of tumors. Particular interest has focused on
whether EPCs incorporate into the growing vascular tree
and, if so, to what extent they contribute to neovascular-
ization.
26–29 VEGF inhibition appears to decrease levels
of EPCs and increase the detachment of mature circulat-
ing endothelial cells (CECs) originating from tumor vas-
culature.
30 Thus it has been suggested that EPCs and
CECs can be used as surrogate markers for disease
progression and efficacy of anti-angiogenic therapy in
tumors.
31
Endometriosis and tumor growth both require angio-
genesis for expansion of mass.
10 Because previous work
has suggested the use of EPCs as an indicator of tumor
growth and regression, in this study we investigated the
role of EPCs as potential biomarkers of endometriosis.
We used an established mouse model of surgically in-
duced endometriosis to measure levels of CECs and
EPCs. Further, we used a bone marrow transplantation
model to quantify the extent of EPC incorporation into the
newly forming vasculature of growing endometriotic le-
sions. Finally, our studies assess the effect of anti-angio-
genic therapy on EPC and CEC levels.
Material and Methods
Animal Handling
All procedures were performed in the animal facility at
Children’s Hospital, Boston, MA. All animal handling and
procedures were performed in accordance with federal,
local, and institutional guidelines and were approved by
the Institutional Animal Care and Use Committee of Chil-
dren’s Hospital. Eight-week-old female 129  1/SvJ mice
were purchased from Jackson Laboratories (Bar Harbor,
MN); 129S6/SvEvTac mice were purchased from Taconic
Farms (Hudson, NY), and C57BL/6 mice were purchased
from Charles River Laboratories (Wilmington, MA).
C57BL/6J-GFP-mice were a generous gift from Dr. Taturo
Udagawa.
32 The mice were caged in groups of five to 10
with free access to chow and water; they were accli-
mated for 3 weeks before any experiment. The animal
room was kept constantly at 26°C, 38.5% humidity, with a
12-hour light, 12-hour dark cycle (7:30 AM to 7:30 PM).
Mice received no hormonal treatment.
Induction of Endometriosis
Mice were randomly taken from different cages to mini-
mize any potential effects of the stage of the estrous
cycle, which was determined by vaginal smears as pre-
viously described.
12 Consequently, the stages were
evenly distributed across the different groups in all ex-
periments (data not shown). All surgical procedures were
performed under inhalational anesthesia with isoflurane
(Baxter, Deerfield, IL), and mice were observed until they
fully recovered. Endometriosis was surgically induced as
described previously.
33–36 Briefly, the uterine horns were
removed through a midline abdominal incision and
opened longitudinally in a Petri dish containing warmed
0.9% saline solution. Four or six biopsy specimens (2 mm
in diameter) were obtained with use of a dermal biopsy
punch (Miltex, Bethpage, NY), and the lesions were au-
totransplanted to the peritoneal wall with the endometrial
side facing the peritoneum using a braided 7–0 silk su-
ture (Ethicon, Somerville, NJ). The wound was closed
with a 5–0 suture (Ethicon). Identical procedures were
performed in the “sham group” except that sutures alone
were inserted instead of endometrial tissue. Mice in the
“control group” did not undergo surgery. For initial exper-
iments (Figure 1), blood was taken 1 week after inocula-
tion with endometriosis. For all of the other experiments,
blood was drawn and mice were sacrificed at the indi-
cated time points. At the end of the experiment, lesions
were measured at their implantation site as described
previously: two perpendicular diameters (D1,D 2) of each
lesion were measured with a caliper to the nearest tenth
of a millimeter.
12,37,38 Lesion volumes were determined
using the formula for a sphere (volume  D1  D2  /4).
Lesions were then excised for further processing. In
some groups of mice the uteri also were removed for
further analysis (described in a later section).
Lodamin Treatment
129S6/SvEvTac mice were divided into three groups
(“endometriosis,” “sham,” and “control”; n  20/group).
Half of the mice received 15 mg/kg Lodamin, an oral
formulation of the angiogenesis inhibitor TNP-470, or ve-
hicle daily by oral gavage for 14 days.
39 Mice were mon-
itored daily for changes in weight. Daily vaginal smears
were taken, and uterine horns were removed at the end of
the experiment to determine the potential effect of
EPCs in Endometriosis 1783
AJP April 2011, Vol. 178, No. 4Lodamin on estrous cycling. In the bone marrow trans-
plantation experiments, C57BL/6J mice with transplanted
green fluorescent protein (GFP) bone marrow received
endometriotic tissue from wild-type C57BL/6J mice.
Bone Marrow Transplantation
Bone marrow transplantation was performed as described
previously.
40 In brief, bone marrow was harvested from
C57BL/6J-GFP mice. The donor mice were euthanized us-
ing carbon dioxide, and their femurs were dissected and
then flushed with 1 mL sterile 0.9% saline solution to collect
bone marrow. Anesthetized recipient C57BL/6 mice
(Charles River Laboratories) were lethally irradiated with
950 Gy. The harvested GFP bone marrow was then injected
into the retro-orbital plexus of into the irradiated recipients in
100 L 0.9% saline solution. The bone marrow was allowed
to engraft for 6 weeks. Engraftment was verified by GFP-
positive blood samples before endometriosis induction.
Flow Cytometry Analysis of Circulating
Endothelial Cells
Circulating EPCs and CECs were measured in the pe-
ripheral blood of all of the mice. After induction of anes-
thesia using isoflurane, 500 L to 1000 L of blood was
collected by retro-orbital puncture and anticoagulated
with use of sodium citrate. Blood was kept on ice until
processing, and 150 L of blood was used to quantify
circulating endothelial cells using four-color flow cytom-
etry as previously described.
30,41,42 Red blood cells were
lysed using FACSLyse Solution (BD Biosciences, San
Jose, CA), according to the manufacturer’s directions.
For the fluorescence-activated cell sorting analysis of
GFP-positive cells in tissue, eutopic endometrium and
endometriotic lesions were taken from mice that had un-
dergone a bone marrow transplantation and wild-type
mice. Tissue was incubated in Dispase 2 (Roche, Nutley,
NJ) for 30 minutes at 37°C per the manufacturer’s instruc-
tions to dissociate tissue into single-cell suspensions,
re-suspended in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum to neutralize enzymes, and
washed in PBS with 1% bovine serum albumin before
staining with antibodies and performing fluorescence-
activated cell sorting analysis.
The following directly conjugated antibodies were
used to detect EPCs and CECs in peripheral mouse
blood: anti-mouse CD45-PerCP, CD31-APC (platelet/en-
dothelial cell adhesion molecule-1), Flk-1-PE (mouse
VEGFR-2; all BD Biosciences, San Jose, CA), and
CD133-fluorescein isothiocyanate (Prominin-1; eBio-
science, San Diego, CA). Tissue was stained with the
same antibodies except the CD133 fluorescein isothio-
cyanate antibody. Flow cytometry was performed us-
ing a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA) and acquired data were analyzed with
FLOWJO flow cytometry analysis software (Treestar, Ash-
land, OR), with analysis gates designed to remove resid-
ual platelets and cellular debris. Fluorescence minus one
control subjects were used for gating. Between 500,000
and 1000,000 events were counted in each sample.
SV40-transformed murine endothelial (MS-1) cells
43 were
spiked into blood samples as a positive control for com-
pensation and gating purposes.
30
Circulating endothelial cells in mouse peripheral blood
were assessed using flow cytometry and then classified
into mature (CECs: CD45
, VEGFR-2
, CD31
, CD133
)
and bone marrow–derived progenitor endothelial cells
(EPCs: CD45
, VEGFR-2
, CD31
, CD133
) as previ-
ously described.
30,41,42,44
Immunohistochemistry
Immunohistochemical staining was carried out on 8-m
frozen sections. For CD31-Cy3 staining, sections were
dried for 2 to 3 hours at room temperature and circled
with an Immedge Pen (Vector Laboratories, Burlingame,
CA). Sections were immersed in 0.3% Triton X-100 PBS
(T-PBS), washed twice with PBS, and then blocked for 1
hour with 5% goat serum (Jackson ImmunoResearch,
Figure 1. Blood EPC numbers in mice. Female mice received endometriotic
(black columns) or sham lesions (gray columns) during abdominal surgery or
were not operated upon (control subjects, white columns). Whole blood was
taken after 1 week and stained for EPC markers (flow cytometry). Female
C57BL/6 mice received four lesions (A) or six lesions (B)( * P  0.05; **P 
0.001, posthoc Bonferroni test). Female 129SvJ mice received six lesions (C).
All experiments were performed with n  10 per group. Values shown are
mean  SEM (*P  0.05; **P  0.007, posthoc Bonferroni test).
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bovine serum albumin  0.01% Thimerosal. The same
solution without goat serum was used to dilute antibod-
ies. Incubation with primary antibody (rat anti-mouse
CD31, 1:500, BD Biosciences) was carried out overnight.
Slides were then washed with T-PBS and incubated with
secondary antibody (Cy3-goat anti-rat 1:400, Jackson
ImmunoResearch) for 4 to 5 hours. Slides were then
washed with T-PBS and fixed with 4% paraformaldehyde
for 15 minutes. The final washes with PBS were done
before mounting with Vectashield Mounting Medium with
DAPI (Vector Laboratories) according to the manufactur-
er’s instructions.
Uterine horns and ovaries were removed from mice in
all groups after Lodamin treatment. Tissues were snap
frozen in liquid nitrogen and mounted in OCT embedding
medium (Thermo Fisher Scientific, Waltham, MA). Sec-
tions that were 5- to 7-m thick were cut on a cryostat
machine and stained with H&E.
Statistics
All statistical comparisons were done using SigmaStat
software (Aspire Software International, Leesburg, VA) as
previously described.
40 The number of mature CECs and
EPCs detected in each mouse was expressed as abso-
lute number of cells per microliter of blood analyzed.
Mean CEC and EPC values were then calculated and
compared between the different groups. Means and Stu-
dent’s t-test for parametric data or median and rank-sum
test for nonparametric data were applied to compare
groups. EPCs in whole blood were compared using one-
way analysis of variance (analysis of variance) with post-
hoc testing based on the Bonferroni procedure to mini-
mize type I errors (false-positive results) due to multiple
group comparisons.
45 Lesion size was compared with
use of repeated-measures analysis of variance.
Results
EPC Levels Are Elevated in a Mouse Model of
Endometriosis
To examine the levels of EPCs in a mouse model of
endometriosis, we initially measured EPC counts by flow
cytometry in C57BL/6 mice with four syngeneic endo-
metriotic lesions. As we have previously described,
30
EPCs were identified by their expression of three cell
surface markers including CD31 (endothelial marker),
Flk-1 (VEGFR-2, endothelial marker), and CD133 (Prom-
inin-1, stem cell marker) and the absence of CD45 (he-
matopoietic cell marker) (see Supplemental Figure S1 at
http://ajp.amjpathol.org). To distinguish between CECs
and EPCs, further characterization was done by gating
on CD133 and CD31 expression. Similar to previous re-
ports, in a typical experiment with C57BL/6 mice we
found 0.2 to 0.5 EPC per microliter of blood and five to 10
CECs per microliter of blood.
30,40 In the presence of four
and six lesions, a highly statistically significant overall
difference between the three groups was observed 1
week after endometriosis surgery (four lesions: F 
51.48, P  0.0001, Figure 1A; six lesions: F  8.41, P 
0.001, Figure 1B). However, the difference between the
endometriosis and sham groups were only marginally
significant or not significant.
Because various inbred murine genetic backgrounds
have been demonstrated to have variable angiogenic
responses,
31,46 we chose to examine one of the most
angiogenic strains, 129/SvJ mice. Thus we implanted six
lesions per mouse into 129/SvJ mice, which have been
shown to have baseline higher circulating EPC levels.
46
Our studies demonstrated a significant overall mean dif-
ference between groups (Figure 1C) (F  7.39, P 
0.003). Statistical analysis further indicated significantly
higher circulating blood EPC levels in the endometriosis
group compared with control subjects (P  0.007) or
compared with mice that underwent a sham operation
(P  0.007) (Figure 1C). No significant difference was
detected between sham treated mice versus control sub-
jects (P  0.99).
CEC and EPC Levels Decrease Over Time
To determine whether the numbers of EPCs or CECs
fluctuated over time after the implantation of endometri-
otic lesions, mice were terminally bled on various days
after disease initiation. We found a highly significant
change in lesion area over time (F  15.78, P  0.001),
with posthoc analysis revealing a significant reduction in
the first 10 days (P  0.04) and then a dramatic increase
from day 10 to day 28 (P  0.001). We next examined the
changes in mean EPCs per microliter of whole blood
between sham and endometriosis groups at specific time
points. Our results indicated overall significantly greater
circulating EPC levels in the endometriosis group (F 
10.54, P  0.002) (Figure 2B) with significant differences
at 1 day (P  0.008), 4 days (P  0.03), and 10 days
(P  0.04) but no differences at 7 days (P  0.48), 14
days (P  0.30), or 28 days (P  0.47).
We then investigated CEC levels in mice that had en-
dometriosis versus mice that underwent a sham opera-
tion over time. Overall, significantly higher CEC levels
were found in the endometriosis group (F  4.21, P 
0.04) (Figure 2C), which was confirmed by posthoc anal-
ysis for day 1 (P  0.001), but not thereafter.
Bone Marrow-Derived Cells Incorporate into the
Vasculature of Endometriotic Implants
Endometriotic lesions were implanted into irradiated wild-
type mice transplanted with GFP-expressing bone marrow.
Endothelial cells in the circulation, in the endometriotic le-
sions, and in the uterine tissue were quantified at various
time points after surgery. Uterine tissue and endometriotic
lesions were isolated and dissociated into single cell sus-
pensions, and endothelial cells were identified using flow
cytometry by the expression of two different cell surface
markers (CD31
 and VEGFR2
) and exclusion of a hema-
topoietic cell surface antigen (CD45
)( Figure 3A). We de-
tected a highly significant increase over time in the numbers
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sions at 21 days (F  31.97, P  0.001) but no change in
uterine tissue (F  1.73, P  0.21).
The percentage of GFP-positive bone marrow–derived
cells was significantly elevated in endometriotic lesions
after 21 days (F  30.62, P  0.001) but remained con-
stant in uterine tissue (F  0.88, P  0.48) (Figure 3B). To
determine whether GFP bone marrow–derived cells were
endothelial cells, we analyzed GFP
 cells that were also
VEGFR2 and CD31 positive but negative for CD45 (Fig-
ure 3C). None of these cells could be detected in the
endometriotic lesions on the day after the transplantation.
Two-way analysis of variance confirmed a highly significant
increase over time in the percentage of GFP-positive endo-
thelial cells in endometriotic tissue (F  33.06, P  0.001)
and in uterine tissue (F  21.69, P  0.003). Furthermore,
incorporation of GFP-positive cells into the vasculature of
endometriotic lesions was confirmed by immunofluores-
cence with an antibody to CD31, an endothelial cell specific
marker that co-localized with GFP expression (Figure 3D).
These studies confirmed the presence of endothelial pro-
genitor cells incorporated into endometriotic lesions.
Lodamin Inhibits the Up-Regulation of EPCs
and CECs
Anti-angiogenic therapy has been shown to suppress
endometriotic growth in various mouse models.
15,37,38
Lodamin is an oral nontoxic formulation of TNP-470, one
of the most potent angiogenesis inhibitors known to
date.
39 Cohorts of wild-type mice were either designated
as control (untouched) or had sham surgery or endo-
metriotic lesions implanted. Mice were then treated daily
with either 15 mg/kg Lodamin or vehicle alone by oral
gavage. Weight loss among the different cohorts was not
statistically significant, indicating the lack of toxicity with
daily Lodamin treatment for 1 week (data not shown).
After 1 week of treatment, blood was drawn to measure
both CEC and EPC concentrations. Statistical analysis
indicated significantly lower CECs per microliter of whole
blood for treatment compared with vehicle in the endo-
metriosis group (P  0.02) but no significant difference
between vehicle and treatment for control (P  0.09) or
sham (P  0.21) groups (Figure 4A).
When we looked at EPCs, overall highly significant
differences were observed (F  6.72, P  0.006), with
significantly lower EPCs per microliter after treatment of
the endometriosis (P  0.001), but no significant differ-
ences in the control group (P  0.11) or the sham group
(P  0.07) (Figure 4B). This finding could indicate that
anti-angiogenic therapy with Lodamin suppresses the
mobilization of both circulating endothelial cells and en-
dothelial progenitor cells in the presence of an angiogen-
esis-dependent disease.
When the lesion size was measured after 1 week of
Lodamin treatment, results indicated a significantly
smaller lesion area in the Lodamin group compared with
vehicle (1.74 mm
2 versus 1.41 mm
2,F 7.99, P  0.022)
(Figure 4C).
Discussion
In the present study we show that circulating endothelial
progenitor cells are elevated in an established mouse
model of endometriosis and provide evidence that
these cells incorporate into the growing vasculature of
the endometriotic lesions. EPC up-regulation appears
to be highest during early lesion establishment, coin-
ciding with increased vascular growth as previously dem-
onstrated.
38 However, treatment with the potent angio-
genesis inhibitor Lodamin resulted in a significant
inhibition of this surge of circulating EPCs and subse-
quent suppression of lesion growth. These findings imply
a potential role for EPCs in the angiogenesis-dependent
growth of endometriotic lesions and may indicate the use
of EPCs as a biomarker of disease progression and sur-
rogate marker of treatment efficacy.
Figure 2. Blood levels of endothelial cells over time. Whole blood was
collected from mice with six endometriotic lesions after different time points
(n  5 per time point and group). A: Following blood collection, endometri-
otic lesions were measured with a caliper using the formula of an ellipse as
previously described.
12,34,37,38,77 Values shown are mean  SEM. B: EPCs
stained negative for CD45 and positive for CD31, VEGRR-2, and CD133 (*P 
0.04; **P  0.008; posthoc Bonferroni test). C: CECs stained negative for
CD45 and CD133 and positive for CD31 and VEGFR-2 [endometriosis group
(black squares); sham operated group (white diamonds)] (**P  0.001;
posthoc Bonferroni test).
1786 Becker et al
AJP April 2011, Vol. 178, No. 4Endometriosis is similar to tumors in that it requires
blood vessel growth for disease establishment and pro-
gression. Although the exact mechanisms are unknown,
angiogenesis has been proposed to occur in endometri-
osis through classic mechanisms such as proliferation of
endothelial and supporting cells, intussusception, and
elongation of existing blood vessels.
16,47 In our current
study, we demonstrate for the first time another possible
mechanism, the incorporation of bone marrow–derived
circulating endothelial progenitor cells into the growing
vascular tree. Blood EPC levels rose within 2 days of
“disease” induction and peaked during the first 10 days,
in a manner that was inversely correlated with the size of
the lesions.
Considerable debate exists about the role of EPCs, in
particular regarding the extent and significance of their
incorporation into tumor vasculature.
28,44 In our study, we
found that up to 37% of all endothelial cells in the lesions
were bone marrow–derived 1 week after transplantation.
No significant increase of general bone marrow–derived
cells in the uterus was observed during this period. How-
ever, the percentage of bone marrow–derived endothe-
lial cells did increase over time, which may be a result of
changes in the estrous cycle in these animals. Human
studies have shown higher blood EPC levels during the
follicular
48 and the luteal phase,
49 but in this model, we
did not see estrous cycle–related differences in blood
EPC levels (data not shown). Eggermont et al demon-
strated in a xenotransplant model that human lesions
contained murine CD31-positive cells as early as day 5
after implantation, peaking around day 15.
50 Because
host endothelial cells invaded the interface between the
peritoneal stroma and the lesion, they suggested that the
source of the endothelial cells most likely was in the prolif-
erating surrounding blood vessels. Our data suggest that
bone marrow–derived endothelial cells may contribute to
this process of blood vessel growth, especially during
early lesion establishment.
Endometriosis is a chronic, progressive disease that
frequently presents with multiple sites of extra-uterine
tissue in the peritoneal cavity. Pro-angiogenic factors
such as VEGF, basic fibroblast growth factor, and IL-8
are elevated in endometriotic tissue, peritoneal fluid, or
serum of patients with endometriosis.
21,51,52 VEGF is a
well-studied mitogen for endothelial cells and strongly
increases vascular permeability.
53 It has been previously
demonstrated that VEGF plays a significant role in the
mobilization of bone marrow– derived progenitor cells for
postnatal neovascularization.
22
Assuming that VEGF is one of the main stimuli for the
recruitment of EPCs in this model, our current data sup-
port our previous findings that showed high VEGF levels
in the transplanted lesions during the first week after
transplantation. This rise and subsequent fall in EPC con-
centration and VEGF expression could be explained by a
hypoxic environment after the lesions lose their blood
supply followed by a normoxic one once the lesions ac-
quire new blood vessels. In fact, we have previously
demonstrated a concomitant rise in levels of hypoxia
inducible factor-1  and its downstream target, VEGF, in
A B C
D
Figure 3. Endothelial cells in endometriotic lesions. After irradiating with lethal doses, mice received GFP
/ bone marrow from donor mice. Six weeks later,
endometriotic lesions from wild-type animals were implanted into these mice. Lesions and uterine tissue were removed at different time points from different mice
(n  5 per group and time point), digested, and single cell suspensions were stained and measured using flow cytometry [endometriotic lesions (black squares);
uterine tissue (white diamonds)]. A: Percentage of CD45
, CD31
, and VEGFR-2
 endothelial cells of all cells were measured. B: Percentage of GFP
 cells of
all cells measured. C: Percentage of CD45
, CD31
, VEGFR-2
, and GFP
 endothelial cells. Values shown are mean  SEM (*P  0.003; **P  0.001; posthoc
Bonferroni test). D: Immunohistochemistry of wild-type endometriotic lesions in irradiated mice with transplanted GFP
 bone marrow. GFP fluorescence (middle
panel) and after staining for CD31 (Cy-3; left panel). Fluorescent confocal microscopy showed some co-localization of GFP
 and CD31
 cells (right panel; bar
 50 mol/L).
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tion.
37 Concentrations of both molecules decline thereaf-
ter when neovascularization results in the delivery of ox-
ygen and nutrients.
38,50 The small, delayed rise in blood
EPC levels in the mice that underwent a sham operation
is possibly due to wound healing in these animals. Other
factors have been shown to stimulate EPC recruitments
such as stromal cell-derived factor-1, placental growth
factor, and matrix metalloprotease-9.
54–56 Interestingly,
they all have been associated with endometriosis.
57–60
Blood levels of mature endothelial cells also rose in
both mice that underwent a sham operation and in mice
with endometriosis, although this effect was delayed in
the sham group. We speculate that wound healing,
mainly of the abdominal wall and uterine stump, resulted
in the shedding of these cells from the local tissue in all
animals. The fact that this phenomenon occurred earlier
in the endometriosis group supports this theory, because
transplantation increases the tissue burden undergoing
regeneration. CEC concentrations in both groups were
similar after a few days, suggesting that most of the
endothelial cells originating from the transplanted lesions
had gone.
Anti-angiogenic therapy may have a role as a novel
therapeutic approach in patients with endometriosis.
9
However, potential teratogenicity and inhibitory effects on
the reproductive system demonstrated by some angio-
genesis inhibitors are posing a significant hurdle to the
clinical testing of angiogenesis inhibitors in patients with
endometriosis.
47,61–63 We previously demonstrated that
the endogenous angiogenesis inhibitor endostatin and
its fragment mP-1 had no negative effects on the re-
productive cycle and offspring of mice, while endo-
metriotic growth was suppressed.
12,34 TNP-470, a syn-
thetic fumagillin analog, is a very powerful angiogenesis
inhibitor that has been shown to inhibit endometriotic
growth
15,64,65 but that caused neurotoxicity in clinical
trials.
66,67 Lodamin is an oral, nontoxic form of the fum-
agillin derivative TNP-470, which inhibits tumor growth
and angiogenesis in mice.
39 Possible TNP-470 mecha-
nisms on endothelial cells include affecting the cell cycle
through p53 activation by binding to methionine amino-
peptidase (MetAP-2), preventing Rac1 activation and in-
duction of p21 (CIP/WAF).
68–70
In our current study we found that Lodamin sup-
pressed the levels of EPCs in the blood of mice that had
endometriosis while inhibiting growth of endometriotic
lesions. We have seen a similar effect with caplostatin
(unpublished data), an injectable, nontoxic formulation of
TNP-470 that inhibited endometriotic growth and angio-
genesis.
38 TNP-470 has been shown to inhibit VEGF-
induced endothelial cell growth, migration, and vascular
hyperpermeability.
71–73 In vitro data suggest that VEGF
expression by tumor cells is inhibited by TNP-470.
74 Be-
cause VEGF is considered to play a central role in bone
marrow recruitment, it is conceivable that TNP-470 treat-
ment inhibits VEGF expression in the endometriotic le-
sions, resulting in a reduced stimulus for EPC mobiliza-
Figure 4. Effect of antiangiogenic treatment on EPCs
and CECs. Female 129 SvJ mice underwent endometri-
osis or sham surgery or no surgery (control subjects) (n
 10 per group). Half of the mice of each group
received 15 mg/kg Lodamin (Tx; black columns), an
oral, nontoxic form of the angiogenesis inhibitor TNP-
470, over 7 days. Control subjects received vehicle (V;
white columns). Whole blood was taken at the end
of the experiment, stained for (A) CEC markers
(CD45
, CD31
, VEGFR-2
, CD133
)( * P  0.02;
two-way analysis of variance) and (B) EPC markers
(CD45
, CD31
, VEGFR-2
, CD133
) (**P  0.001;
two-way analysis of variance) and measured using
flow cytometry. C: Endometriosis-like lesions were
measured with a caliper using the formula of an ellipse.
Mean cross-sectional area of endometriosis-like lesions
(n6 lesions) of mice treated with vehicle or Lodamin
(*P  0.022; repeated-measures analysis of variance).
Values shown are mean  SEM.
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75 We have previously demonstrated that VEGF is
highly up-regulated in endometriotic tissue through hyp-
oxia inducible factor-1 .
37 Therefore if the TNP-470 de-
rivative Lodamin inhibits this pathway it could explain the
effect on EPC levels in the treated animals. In fact,
Lodamin inhibits VEGF-induced angiogenesis in a mouse
corneal micropocket assay.
39 Treatment with Lodamin
resulted in the arrest of the estrous cycle at metestrus
(data not shown). Therefore it is conceivable that the
potential effect of the drug on estrogen levels also may
affect EPC (and CEC levels). This question is currently
under investigation.
In summary, we demonstrate that bone marrow–de-
rived endothelial cells contribute to neovascularization in
a mouse model of endometriosis. These findings high-
light the importance of angiogenesis in the establishment
and growth of endometriotic lesions, and they also sup-
port the hypothesis that endothelial progenitor cells are
involved in the pathogenesis of the disease.
76 From a
clinical perspective it will be highly interesting to investi-
gate EPC and CEC levels in women who have the dis-
ease and the effect of therapy on these levels. If circu-
lating endothelial progenitor and mature endothelial cells
are elevated in patients, they may be promising and
much needed biomarkers for both diagnosis and thera-
peutic efficacy.
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